title: Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53.
abstract: Synergistic interaction between H-ras and p53 were systematically examined during skin tumorigenesis. Concurrent expression of an activated H-ras gene and a mutant p53 gene was accomplished by crossing p53(Val135/wt) mice with TG.AC mice. Topical application to wild-type mice with benzo(a)pyrene (BaP) alone produced approximately 26% skin tumor incidence, whereas BaP treatment of p53(wt/wt)Hras(TG.AC/wt), p53(Val135/wt)Hras(wt/wt), and p53(Val135/wt)Hras(TG.AC/wt) mice produced a 75%, 77%, and 100% incidence of skin tumors, respectively. An average of 0.33 tumor per mouse was observed in wild-type (p53(wt/wt)Hras(wt/wt)) mice, whereas approximately 1.54, 1.96, and 3.08 tumors per mouse were seen in BaP-treated p53(wt/wt)Hras(TG.AC/wt), p53(Val135/wt)Hras(wt/wt), and p53(Val135/wt)Hras(TG.AC/wt) mice, respectively. The effects on total tumor volume were even more striking with 7-, 48-, and 588-fold increases in tumor volume compared with wild-type (p53(wt/wt)Hras(wt/wt)) in p53(wt/wt)Hras(TG.AC/wt), p53(Val135/wt)Hras(wt/wt), and p53(Val135/wt)Hras(TG.AC/wt) mice, respectively. Histopathologically, all tumors from p53(wt/wt)Hras(wt/wt) mice were either papillomas or well-differentiated squamous cell carcinomas, whereas the tumors in p53(wt/wt)Hras(TG.AC/wt), p53(Val135/wt)Hras(wt/wt), and p53(Val135/wt)Hras(TG.AC/wt) mice were principally squamous cell carcinomas with varying degree of invasiveness. Particularly, tumors in p53(Val135/wt)Hras(TG.AC/wt) mice exhibited the most rapid growth and the extreme form of tumor invasion. Microarray analysis revealed that dominant-negative p53 (Val135) and activated H-ras affected several cellular processes involved in tumorigenesis possibly through its effects on apoptosis, cell cycle arrest, and Ras-mitogen-activated protein kinase pathways. The present study provides the first in vivo evidence that a germ line p53 mutation and activated H-ras act synergistically to profoundly enhance tumor progression.
authors.affiliation: Department of Surgery and The Alvin J. Siteman Cancer Center, Washington University School of Medicine, 660 Euclid Avenue, Box 8109, St. Louis, Missouri 63110, USA.
authors.forename: Zhongqiu
authors.initials: Z
authors.lastname: Zhang
authors.forename: Ruisheng
authors.initials: R
authors.lastname: Yao
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.forename: Yian
authors.initials: Y
authors.lastname: Wang
authors.forename: Charles W
authors.initials: CW
authors.lastname: Boone
authors.forename: Ronald A
authors.initials: RA
authors.lastname: Lubet
authors.forename: Ming
authors.initials: M
authors.lastname: You
mesh_terms: D000818:Animals; D001564:Benzo(a)pyrene; D002273:Carcinogens; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000235:genetics*; D003043:Cocarcinogenesis; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D011905:Genes, ras / Q000235:genetics*; D018095:Germ-Line Mutation; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D010212:Papilloma / Q000139:chemically induced / Q000235:genetics; D012878:Skin Neoplasms / Q000139:chemically induced / Q000235:genetics*
chemical_list: D002273:Carcinogens; D001564:Benzo(a)pyrene